SLC16A3 and cancer: The aim of this study was to determine if it is possible to destroy the defiance of cancer cells by targeting glycolytic activity and the associated capacity to export lactate via MCT4, enhancing the possibility of immunological recognition, especially by restoring or enhancing the cytotoxic potency of NK cells, and thereby representing a potential new anticancer therapeutic strategy.